Incidence, and factors associated with moderate/severe pediatric traumatic brain injury in children aged 5–15 years in western, Mexico

The study objectives were to estimate the standardized incidence and evaluate factors associated with moderate/severe pediatric traumatic brain injury (p-TBI) in children aged 5–15 years in Western, Mexico. The study was cross-sectional in design. We estimated the standardized incidence of moderate/...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of paediatric neurology 2024-03, Vol.49, p.6-12
Hauptverfasser: Valdivia-Tangarife, Edgar Ricardo, Morlett-Paredes, Alejandra, Rizo-Curiel, Genoveva, Jiménez-Maldonado, Miriam E., Ruiz-Sandoval, José Luis, Barba, Annette Reyes, López-Enríquez, Adriana, Avilés-Martínez, Karla Isis, Villaseñor-Cabrera, Teresita
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The study objectives were to estimate the standardized incidence and evaluate factors associated with moderate/severe pediatric traumatic brain injury (p-TBI) in children aged 5–15 years in Western, Mexico. The study was cross-sectional in design. We estimated the standardized incidence of moderate/severe p-TBI using the direct methods of the World Health Organization (WHO) standard populations. We utilized the Glasgow Coma Scale (GCS) to identify moderate/severe p-TBI patients (GCS ≤ 13). Logistic regression analysis was applied to evaluate variables associated with moderate/severe p-TBI. The standardized incidence of patients diagnosed with moderate/severe p-TBI was 31.0/100,000 person-years (95 % CI 28.7–33.4). According to age, the moderate/severe TBI group was included. A total of 254 (38.5 %) patients were aged 5–9 years, 343 (52.0 %) were aged 10–14 years, and 62 (9.5 %) were aged 15 years. Factors associated with moderate/severe TBI in the crude analysis were male sex (OR 5.50, 95 % CI 4.16–7.39, p 
ISSN:1090-3798
1532-2130
DOI:10.1016/j.ejpn.2024.01.001